M. MAETANI, N. KATO, V. A. P. JABOR, F. A. CALIL, M. C. NONATO, C. A. SCHERER, S. L. SCHREIBER* (HARVARD UNIVERSITY, BROAD INSTITUTE, AND HOWARD HUGHES MEDICAL INSTITUTE, CAMBRIDGE, USA; UNIVERSITY OF SÃO PAULO, BRAZIL)
Discovery of Antimalarial Azetidine-2-carbonitriles that Inhibit *P. falciparum* Dihydroorotate Dehydrogenase
ACS Med. Chem. Lett. **2017**, 8, 438–442.

Synthesis of Dihydroorotate Dehydrogenase Inhibitor BRD9185

Significance: Dihydroorotate dehydrogenase (DHODH) is necessary for pyrimidine biosynthesis in protozoan parasites of the genus *Plasmodium*, the causative agents of malaria. BRD9185 is a DHODH inhibitor that has in vitro activity against multidrug-resistant blood-stage parasites ($\text{EC}_{50} = 0.016 \mu\text{M}$) and is curative after just three doses in a *P. berghei* mouse model. BRD9185 has a long half-life (15 h) and low clearance in mice.

Comment: The key step in the synthesis depicted was the construction of the azetidine-2-carbonitrile core by a 4-exo-tet cyclization of the anion derived from **D**. The stereochemistry of the cyclization depended on the base. Treatment of **D** with LiHMDS at $-50 ^\circ\text{C}$ provided the products **Ea** and **Eb** in a ratio of approximately 15:1 as a separable mixture. Alternatively, exposure of **D** to KHMDS at $-78 ^\circ\text{C}$ gave nearly exclusively **Eb** (**Ea/Eb** $\approx 1:20$). The conversion of **A** into **E** is described in a preceding paper: J. T. Lowe et al. *J. Org. Chem.* **2012**, 77, 7187.

SYNFACTS Contributors: Philip Kocienski
Synfacts 2017, 13(07), 0675 Published online: 19.06.2017
DOI: 10.1055/s-0036-1590519; Reg-No.: K02617SF